



KABRADRUGSLIMITED

CIN-L02423MP1989PLC005438

To,
The Corporate Relationship Manager,
Department of Corporate Services,
BSE Ltd. P J Towers,
Dalal Street, Mumbai – 400001

November 4, 2022

Kabra Drugs Limited, Scrip Code: 524322

Subject : Revised Outcome of Board Meeting held on Wednesday , 2 November 2022

Reference: Your Email dated 3rd November

Dear Sir,

In compliance with provisions of Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015, we like to inform you that Muralidharan R Director has resigned due to personal reasons effective from November 2, 2022. The resignation been accepted by the Board of Directors held today ie. 2 November 2022.

Please take the same on your record.

Thanking You,

Yours Faithfully,

For Kabra Drugs Limited

Director / Authorised Signatory



REGD OFFC: SHOP NO. 270, SHASTRI MARKET, INDORE M.P.

PHONE NO 0731-4247626

Email – kabradrugs@gmail.com, [website- www.kabradrugs.com](http://www.kabradrugs.com)

The details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 are given below:

Sr. No.	Particulars	Details
1	Reason for change viz. appointment, resignation, removal, death or otherwise	Resignation; Mr. Muralidharan R has tender his resignation due to personal reasons and shall not be able to discharge the duties of the Independent Director of the Company.
2	Date of appointment/ cessation (as applicable) & Term of appointment	2 nd November, 2022 (end of Business Hours)
3	Brief Profile (in case of appointment)	NA
4	Disclosure of Relationships between Directors (in case of appointment of a Director)	NA

